Media coverage about Momenta Pharmaceuticals (NASDAQ:MNTA) has trended positive recently, Accern Sentiment reports. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Momenta Pharmaceuticals earned a news sentiment score of 0.29 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 44.2630694911924 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Several equities analysts have recently weighed in on MNTA shares. Zacks Investment Research upgraded shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. ValuEngine upgraded shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, February 23rd. BidaskClub downgraded shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Finally, Stifel Nicolaus reiterated a “hold” rating and issued a $18.00 target price on shares of Momenta Pharmaceuticals in a research note on Tuesday, January 30th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and one has issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $15.33.
Momenta Pharmaceuticals (MNTA) opened at $18.50 on Monday. The company has a market cap of $1,421.88, a P/E ratio of -15.16 and a beta of 1.72. Momenta Pharmaceuticals has a 12 month low of $11.85 and a 12 month high of $19.25.
In related news, CEO Craig A. Wheeler sold 35,666 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $14.11, for a total transaction of $503,247.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Elizabeth Stoner sold 5,500 shares of the business’s stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $13.10, for a total transaction of $72,050.00. Following the transaction, the director now directly owns 13,240 shares of the company’s stock, valued at approximately $173,444. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 112,002 shares of company stock valued at $1,733,746. 4.40% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION WARNING: “Positive Media Coverage Somewhat Unlikely to Affect Momenta Pharmaceuticals (MNTA) Stock Price” was published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3257287/positive-media-coverage-somewhat-unlikely-to-affect-momenta-pharmaceuticals-mnta-stock-price.html.
Momenta Pharmaceuticals Company Profile
Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.